Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Glucosidase I CRISPR/Cas9 KO Plasmid (h): sc-405014
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Glucosidase I CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Glucosidase I genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Glucosidase I Antibody (C-11): sc-374006
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Glucosidase I CRISPR/Cas9 KO Plasmid (h) | sc-405014 | 20 µg | $397.00 |
Overview
MOGS encodes glucosidase I, an endoplasmic reticulum (ER) lumen enzyme that initiates N-linked glycan processing by removing the terminal α-1,2–linked glucose from Glc₃Man₉GlcNAc₂ on nascent glycoproteins. This early trimming step coordinates entry into the calnexin/calreticulin quality-control cycle, influencing protein folding, ER-associated degradation, and secretory pathway maturation. Disruption of MOGS perturbs proteostasis and alters glycoprotein composition at the cell surface and in secreted proteins, with downstream effects on receptor trafficking and immune recognition. Genetic variation or functional loss of glucosidase I has been linked to congenital disorders of glycosylation and broader ER-stress–associated phenotypes, making it relevant for studying glycoprotein-dependent cellular processes.
Glucosidase I CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MOGS gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MOGS together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MOGS open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Glucosidase I protein expression.
This CRISPR knockout system enables efficient generation of MOGS-deficient cell models for investigation of Glucosidase I signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MOGS exon(s) critical for Glucosidase I function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MOGS genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Glucosidase I CRISPR/Cas9 KO Plasmid (h) and Glucosidase I CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MOGS locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Glucosidase I HDR Plasmid (h) and Glucosidase I HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MOGS homology arms to support homology-directed repair at defined MOGS target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.